Skip to main content

DiaMedica Therapeutics Inc.

corporate_fare Company Profile

DiaMedica Therapeutics Inc.

DMAC·NASDAQ·Life Sciences·CIK 0001401040

We are a clinical-stage biopharmaceutical company focused on developing therapies for severe ischemic disease. Our two main clinical programs target preeclampsia (PE) / fetal growth restriction (FGR) and acute ischemic stroke (AIS). Our lead candidate, DM199 (rinvecalinase alfa), is a recombinant form of the human tissue kallikrein-1 (rhKLK1) protein. DM199 has received Fast Track Designation from the U.S. Food and Drug Administration (FDA) for the treatment of AIS. Kallikrein-1 (KLK1) from human urine and pig pancreas is an established treatment in Asia for AIS and cardio renal disease, including hypertension, respectively. We aim to advance DM199 through clinical trials for PE, FGR, and AIS. Our longer-term plan includes developing DM300, our patented recombinant human ulinastatin, as a potential therapy for severe acute pancreatitis. KLK1 is a serine protease enzyme that regulates physiological processes by enhancing endothelial health, microcirculatory blood flow, and tissue perfusion through increased production of nitric oxide (NO), prostacyclin (PGI 2 ), and endothelium-derived hyperpolarizing factor (EDHF). For PE and FGR, DM199 is designed to lower blood pressure, improve endothelial health, and enhance perfusion to maternal organs and the placenta. For AIS, DM199 aims to increase blood flow and neuronal survival in the ischemic penumbra by dilating arterioles and inhibiting apoptosis, while also promoting neuronal remodeling through angiogenesis. Our clinical development program for PE involves an investigator-sponsored Phase 2 study at Tygerberg Hospital in Cape Town, South Africa, assessing safety, tolerability, and pharmacodynamics.

DiaMedica Therapeutics Inc. (NASDAQ:DMAC) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 12 items for DMAC at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-12, rated 7/10. Across its 12 most recent items scored 7 or higher, the top rating is 8/10, with 6 rated 8 or above. Recent SEC coverage for DMAC spans 8-K, 10-Q, DEF 14A.

Recent high-impact activity:

  • DiaMedica Q3 Loss Widens to $11.3M; ReMEDy2 Hits 200-Patient Interim Analysis Threshold
  • DiaMedica Q2 Loss Widens to $10.1M; ReMEDy2 Stroke Trial Hits 85% Enrollment, Interim Analysis Set for Q1 2027
  • DiaMedica's Preeclampsia Drug Shows Strong Blood Pressure Reductions in Phase 2
  • Shareholders Approve 3.5M Share Increase for Incentive Plan
  • DiaMedica's Pivotal Stroke Trial Reaches 75% Enrollment, Signaling Progress After Prior Delays

Financial Snapshot

Fiscal year ended December 31, 2025
Net Income
-$32.77M
Op. Cash Flow
-$29.06M
Free Cash Flow
-$29.1M
Operating Income
-$34.4M
Cash & Equivalents
$15.65M
Debt / Equity
0.00×
Shares Outstanding
53.74M sh
Source: 10-K · filed 2026-03-30 · accession 0001437749-26-010342

Short Interest & Short Volume

24.77 days to cover

FINRA reported short interest of 5,018,365 shares in DMAC as of the October 30, 2026 settlement, a 4.2% decrease from the prior period — about 24.8 days to cover at its recent average daily volume. On November 20, 2026, 32.9% of DMAC volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)5,018,365 shares as of October 30, 2026
Change vs prior period▼ 4.2%
Days to cover24.77 at avg daily volume of 202,577
Daily short volume (FINRA facilities)32.9% of 125,849 shares on November 20, 2026
5-day average short volume37.8%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Browse all tickers starting with D →
$8.25
52-week range · as of 2026-11-12 $5.25 – $11
Market cap
$445.15M
Volume
313.5K (1.4× avg)
3-mo avg 230.2K
Live data · 2026-11-22 01:19 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed DMAC - Latest Insights

DMAC
Nov 12, 2026, 4:40 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $9.33
Real-time Price: $8.25 info
Change: -$1.08 (-12%) info
Market Cap: $445.149M info
DMAC
Aug 10, 2026, 4:37 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $6.58
Real-time Price: $8.25 info
Change: +$1.67 (+25%) info
Market Cap: $445.149M info
DMAC
Aug 10, 2026, 4:30 PM EDT
Source: BusinessWire
Importance Score:
8
Price at Filing: $6.58
Real-time Price: $8.25 info
Change: +$1.67 (+25%) info
Market Cap: $445.149M info
DMAC
May 21, 2026, 4:30 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $5.77
Real-time Price: $8.25 info
Change: +$2.48 (+43%) info
Market Cap: $445.149M info
DMAC
May 20, 2026, 8:57 AM EDT
Source: Reuters
Importance Score:
8
Price at Filing: $5.57
Real-time Price: $8.25 info
Change: +$2.68 (+48%) info
Market Cap: $445.149M info
DMAC
May 06, 2026, 5:08 PM EDT
Source: Reuters
Importance Score:
7
Price at Filing: $6.52
Real-time Price: $8.25 info
Change: +$1.73 (+27%) info
Market Cap: $445.149M info
DMAC
May 06, 2026, 4:38 PM EDT
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $6.52
Real-time Price: $8.25 info
Change: +$1.73 (+27%) info
Market Cap: $445.149M info
DMAC
Apr 01, 2026, 4:06 PM EDT
Filing Type: DEF 14A
Importance Score:
7
Price at Filing: $6.42
Real-time Price: $8.25 info
Change: +$1.83 (+29%) info
Market Cap: $445.149M info
DMAC
Mar 30, 2026, 6:40 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $6.64
Real-time Price: $8.25 info
Change: +$1.61 (+24%) info
Market Cap: $445.149M info
DMAC
Mar 30, 2026, 4:45 PM EDT
Source: Dow Jones Newswires
Importance Score:
8
Price at Filing: $6.64
Real-time Price: $8.25 info
Change: +$1.61 (+24%) info
Market Cap: $445.149M info
DMAC
Mar 05, 2026, 7:36 AM EST
Source: Reuters
Importance Score:
8
Price at Filing: $7.77
Real-time Price: $8.25 info
Change: +$0.480 (+6%) info
Market Cap: $445.149M info
DMAC
Jan 05, 2026, 9:16 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $8.15
Real-time Price: $8.25 info
Change: +$0.100 (+1%) info
Market Cap: $445.149M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets